CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 108 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $116,178,662 | +41.4% | 7,791,996 | +3.8% | 0.00% | +50.0% |
| Q2 2023 | $82,176,135 | +255.6% | 7,504,670 | +183.2% | 0.00% | +100.0% |
| Q1 2023 | $23,108,674 | +82.9% | 2,650,077 | +31.5% | 0.00% | – |
| Q4 2022 | $12,637,184 | +85.7% | 2,015,500 | +3.6% | 0.00% | – |
| Q3 2022 | $6,806,000 | +18.2% | 1,944,650 | -0.4% | 0.00% | – |
| Q2 2022 | $5,759,000 | -66.1% | 1,952,869 | -64.3% | 0.00% | – |
| Q1 2022 | $16,998,000 | -5.5% | 5,466,209 | +2.7% | 0.00% | – |
| Q4 2021 | $17,994,000 | -5.3% | 5,324,128 | +2.3% | 0.00% | -100.0% |
| Q3 2021 | $19,001,000 | -19.8% | 5,205,478 | -4.2% | 0.00% | 0.0% |
| Q2 2021 | $23,682,000 | -12.5% | 5,431,670 | -8.8% | 0.00% | 0.0% |
| Q1 2021 | $27,052,000 | -12.5% | 5,958,488 | +10.6% | 0.00% | 0.0% |
| Q4 2020 | $30,916,000 | -16.8% | 5,386,244 | +5.0% | 0.00% | 0.0% |
| Q3 2020 | $37,147,000 | +89.5% | 5,130,908 | -8.6% | 0.00% | 0.0% |
| Q2 2020 | $19,601,000 | +139.4% | 5,616,562 | +1.5% | 0.00% | – |
| Q1 2020 | $8,187,000 | -25.3% | 5,531,588 | -1.0% | 0.00% | – |
| Q4 2019 | $10,957,000 | -62.0% | 5,589,851 | -0.7% | 0.00% | -100.0% |
| Q3 2019 | $28,817,000 | -27.2% | 5,628,239 | +1.8% | 0.00% | -50.0% |
| Q2 2019 | $39,600,000 | -40.8% | 5,530,692 | +9.8% | 0.00% | -33.3% |
| Q1 2019 | $66,892,000 | +64.7% | 5,037,030 | -2.4% | 0.00% | +50.0% |
| Q4 2018 | $40,622,000 | -17.4% | 5,161,581 | +16.3% | 0.00% | 0.0% |
| Q3 2018 | $49,184,000 | -9.6% | 4,438,828 | +9.5% | 0.00% | -33.3% |
| Q2 2018 | $54,410,000 | +258.3% | 4,054,285 | +246.8% | 0.00% | +200.0% |
| Q1 2018 | $15,187,000 | +139.0% | 1,169,203 | +69.3% | 0.00% | – |
| Q4 2017 | $6,354,000 | +28.6% | 690,679 | +12.6% | 0.00% | – |
| Q3 2017 | $4,942,000 | +372.9% | 613,220 | +238.2% | 0.00% | – |
| Q2 2017 | $1,045,000 | +103.7% | 181,324 | +51.9% | 0.00% | – |
| Q1 2017 | $513,000 | – | 119,345 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |